The practical impact of altered dosing on perampanel plasma concentrations: pharmacokinetic modeling from clinical studies.

@article{Gidal2014ThePI,
  title={The practical impact of altered dosing on perampanel plasma concentrations: pharmacokinetic modeling from clinical studies.},
  author={B E Gidal and Oneeb Majid and Jim Ferry and Ziad Hussein and Haichen Yang and Jin Zhu and Randi Fain and Antonio Laurenza},
  journal={Epilepsy & behavior : E&B},
  year={2014},
  volume={35},
  pages={6-12}
}
RATIONALE Perampanel is a selective AMPA receptor antagonist approved for adjunctive therapy in patients with refractory partial-onset seizures. Perampanel is metabolized primarily via CYP3A4, yet it has a relatively long half-life of 105h; it is, therefore, recommended that perampanel be given once daily (preferably at bedtime). Many patients occasionally have less-than-perfect adherence to their drug regimen, and given the known pharmacokinetic interactions of perampanel with commonly used… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 23 references

Impact of delayed dose or missed dose on perampanel plasma concentrations

  • BE Gidal, O Majid, J Ferry
  • Poster presented at: 66th American Epilepsy…
  • 2012
Highly Influential
14 Excerpts

Population pharmacokinetics and pharmacodynamics of perampanel in patients with refractory partial seizures

  • E Fuseau, D Templeton, Z. Hussein
  • Epilepsy Curr 2011;11(Suppl
  • 2011
1 Excerpt

Population pharmacokinetics and pharmacodynamics of perampanel: a pooled analysis from three phase III trials

  • A Laurenza, J Ferry, Z. Hussein
  • Poster presented at: 65th American Epilepsy…
  • 2011
1 Excerpt

Similar Papers

Loading similar papers…